Based on the above-mentioned Eli Lilly and Pfizer developed structure (compound 40), they developed EGFR and ATX dual inhibitors on this tetrahydropyrimidine scaffold considering the key role of EGFR in lung fibrosis caused by lung cancer, and obtained compounds 67 (IC50 = 38.4/42.3 nM, ATX/EGFR) and 68 (IC50 = 29.1/24.2 nM, ATX/EGFR). This evidence concerns the gene EGFR and pulmonary fibrosis.